Canada Soccer and Haleon Kickoff Multi-Year Partnership focused on Health and Wellness Français
"Soccer is one of the most accessible and fastest-growing sports in the country, as it can be played by anyone, anywhere," said Syed Zeeshan Shams, Head of Marketing for Haleon Canada. "Self-care and prevention are the best defense, and Haleon's products can assist Canadians, including athletes at all levels, in maintaining their health and performance."
The partnership will kick-off with Canada Soccer's National Teams' 2025 international match schedule building toward Canada's participation in FIFA World Cup '26 on home soil and through the much-anticipated 2027 FIFA Women's World Cup. Haleon will bring the partnership to life through online, in-stadium and retailer activations, designed to create unforgettable moments for soccer fans across Canada.
"The enthusiasm and energy for soccer continues to grow among Canadians," said Dominic Martin, Director of Marketing, Canada Soccer. "We are proud to introduce this collaboration which highlights the shared values of both Haleon and Canada Soccer in fostering a culture of proactive health management and peak performance on and off the pitch."
This marks Haleon Canada's first national, full-portfolio sponsorship.
"Haleon and Canada Soccer are very much aligned in their approaches to health and wellness, so it's fitting that they are now partnering to promote such essential principles," said Glen Johnson, Executive Vice President, Canadian Soccer Business. "We look forward to supporting them in leveraging this relationship to benefit fans of soccer on and off the pitch in the coming years."
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Wellness. Built on trusted science, innovation and deep human understanding, Haleon Canada brands include: Advil, Buckley's, Centrum, Emergen-C, Flonase, NeoCitran, Nexium, Polident, Robitussin, Sensodyne, TUMS, Voltaren and more. For more information on Haleon and its brands visit www.haleon.com.
About Canada Soccer
Canada Soccer, in partnership with its membership and its partners, provides leadership in the pursuit of excellence in soccer, both at the national and international levels. Canada Soccer not only strives to lead Canada to victory, but also encourages Canadians to a life-long passion for soccer. For more details on Canada Soccer, visit the official website at www.canadasoccer.com.
About Canadian Soccer Business
Canadian Soccer Business (CSB) represents a suite of top-tier national assets that are central to the sport of soccer in Canada. This includes representation for all corporate partnerships and media rights (broadcast and distribution) related to Canada Soccer's core assets including the Men's and Women's National Team and the TELUS Canadian Championship, along with all rights associated with the Canadian Premier League (CPL) and League1 Canada.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Stock Market Today: Nio Rises 8% on Onvo L90 Launch Success Amid Soft Tech Market
Chinese electric vehicle (EV) maker Nio 's (NYSE: NIO) stock price jumped 8% on Thursday to close at $4.87, outpacing the broader market after its mass-market sub-brand Onvo reported an explosive start to L90 SUV sales. The stock hit an intraday high of $4.98. While shares remain about 37% below their 52-week high of $7.71, today's rally was one of the largest among U.S.-listed EV names. The S&P 500 declined 0.4% and the Nasdaq Composite edged down 0.03%, as investors digested a mix of earnings and macroeconomic updates. Nio's strong upside stood in contrast to most of the tech sector. Peer EV makers underperformed. Rivian Automotive (NASDAQ: RIVN) fell 1.2% to $12.87 amid concerns over a 22% drop in Q2 deliveries. Lucid Group (NASDAQ: LCID) slipped 1.6% to $2.46 despite a modest rebound earlier this month, as analysts remain cautious on demand trends. The surge in Nio's share price followed news that its newly launched Onvo L90 SUV sold out its first 10,000-unit batch within three hours of opening online reservations. Analysts cited the quick sellout as a major sign of consumer interest in NIO's push into the mass market. The Onvo brand now accounts for roughly 40% of Nio's monthly deliveries. Deutsche Bank analysts estimate Nio generated approximately 26,000 orders in July, up 11% month-over-month and ahead of local EV rivals. Management reiterated a goal to reach adjusted profitability by Q4 2025, with a longer-term plan to scale margin expansion and infrastructure like battery swaps and autonomous driving chips. Should you invest $1,000 in Nio right now? Before you buy stock in Nio, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nio wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Daily Stock News has no position in any of the stocks mentioned. This article was generated with GPT-4o, OpenAI's large-scale language-generation model and has been reviewed by The Motley Fool's AI quality control systems.
Globe and Mail
2 hours ago
- Globe and Mail
Why AbbVie Stock Slumped Today
Key Points It had a good second quarter, fueled by sales growth in top blockbuster drugs. It also topped analyst estimates for both revenue and profitability. 10 stocks we like better than AbbVie › Shares of AbbVie (NYSE: ABBV) were bouncing along merrily for most of Thursday's trading session, until news of a fresh demand from the White House quashed the rally. Initially, the market was cheered by better-than-expected quarterly results published by the company that morning. Ultimately AbbVie's stock closed down slightly lower in price, roughly mirroring the trajectory of the S&P 500 index. Second-quarter rises That late-session swoon was kind of a shame, because AbbVie's second quarter boasted some good fundamentals. Total revenue came in at just over $15.4 billion, an increase of almost 7% over the year-ago result. Of its blockbuster drugs, Skyrizi did quite well, with sales rising 62% to $4.4 billion. Rinvoq also rocketed higher, by 42% to more than $2 billion. On the other hand, the fading Humira -- now that it's been subject to competition by biosimilars -- fell by 58% to less than $1.2 billion. As for net income, on a non-GAAP (adjusted) basis it landed at nearly $5.3 billion, or $2.97 per share. That was well up from the year-ago profit of $4.7 billion. On average, the pundits tracking AbbVie stock were collectively expecting a shade under $15 billion for revenue, and $2.96 per share for adjusted profitability. AbbVie raised its bottom-line guidance for the entirety of 2025. It now believes adjusted net income will amount to $11.88 to $12.08 per share, up from the previous estimate of $11.67 to $11.87. Trump's new move The bullishness generated by those fundamentals and the lifted guidance was tempered by the latest demand from President Donald Trump. Thursday afternoon, news broke that he sent letters to a clutch of major U.S. pharmaceuticals insisting that they reduce prices for prescription drugs within 60 days. One of the letters was sent to AbbVie CEO Rob Michael. In it, Trump wrote, "Right now, brand name drug prices in the United States are up to three times higher on average than elsewhere for the identical medicines." "This unacceptable burden on hardworking American families ends with my administration," the president added. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
Globe and Mail
2 hours ago
- Globe and Mail
BRW Announces Notification of Sources of Distributions
Saba Capital Income & Opportunities Fund (NYSE: BRW) (the 'Fund'), a registered closed-end management investment company listed on the New York Stock Exchange, is notifying shareholders, prospective shareholders, and third parties of the sources of distributions pursuant to Section 19(a) of the Investment Company Act of 1940 (the 'Investment Company Act'). IMPORTANT INFORMATION REGARDING MONTHLY DISTRIBUTION Distribution Notice. Pursuant to Section 19(a) of the Investment Company Act, the Fund is providing its shareholders with an estimate of the source of the Fund's monthly distribution as required by current securities laws. The Fund's estimated sources of the distribution to be paid on July 31, 2025 and for the fiscal year 2025 year-to-date are as follows: Estimated Allocations for the distribution to be paid on July 31, 2025 (estimated as of July 24, 2025): Cumulative Estimated Allocations fiscal year-to-date as of June 30, 2025, for the fiscal year ending October 31, 2025: Distribution Per Share Net Investment Income Per Share and Percentage of Such Distribution Amount Net Realized Short-Term Capital Gains Per Share and Percentage of Such Distribution Amount Net Realized Long-Term Capital Gains Per Share and Percentage of Such Distribution Amount Return of Capital Per Share and Percentage of Such Distribution Amount $0.68000 $0.41295 (60.73%) $0.00000 (0.00%) $0.00000 (0.00%) $0.26705 (39.27%) Shareholders, prospective shareholders, and third parties should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's Plan (as defined below). The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of the Fund's distribution to shareholders may be a return of capital. A return of capital may occur, for example, when some or all of the money that a shareholder invested in a Fund is paid back to them. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with 'yield' or 'income.' The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send a Form 1099-DIV to shareholders for the calendar year that will describe how to report the Fund's distributions for federal income tax purposes. The determination of the actual source of distributions can only be made at year-end. The actual source amounts of all Fund distributions will be included in the Fund's annual or semi-annual reports. In addition, the tax treatment may differ from the accounting treatment used to calculate the source of the Fund's distributions as shown on shareholders' statements. Shareholders should refer to their Form 1099-DIV for the character and amount of distributions for income tax reporting purposes. The final determination of the source and tax characteristics of all distributions will be made after December 31, 2025 and reported to you on Form 1099-DIV early in 2026. Since each shareholder's tax situation is unique, it may be advisable to consult a tax advisor as to the appropriate treatment of Fund distributions. Effective after the close of business on June 4, 2021, Saba Capital Management, L.P. replaced Voya Financial as the investment adviser to Saba Capital Income & Opportunities Fund (formerly known as the Voya Prime Rate Trust). Performance of the Fund prior to the close of business on June 4, 2021 is not attributable to Saba Capital Management, L.P. Average Annual Total Return (in relation to the change in net asset value (NAV) for the 5-year period ended on June 30, 2025) 1 Annualized Distribution Rate (for the current fiscal period as a percentage of NAV as of June 30, 2025) 2 Cumulative Total Return (in relation to the change in NAV for the current fiscal period through June 30, 2025) 3 Cumulative Fiscal Year-To-Date Distribution Rate (as a percentage of NAV as of June 30, 2025) 4 9.82% 12.24% 15.67% 8.00% Fund Performance and Distribution Rate Information: 1 Average Annual Total Return in relation to NAV represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ended through June 30, 2025. Annual NAV Total Return is the percentage change in the Fund's NAV over a year, assuming reinvestment of distributions paid. 2 The Annualized Distribution Rate is the dollar value of distributions for the current fiscal period November 1, 2024 through June 30, 2025 annualized as a percentage of the Fund's NAV as of June 30, 2025. The level of distribution amount shown is not guaranteed and special dividends may or may not be paid in the future. Further, no conclusions should be drawn about the Fund's investment performance from the amount or rate of distribution shown. 3 Cumulative Total Return is the percentage change in the Fund's NAV from October 31, 2024 through June 30, 2025, assuming reinvestment of distributions paid. 4 The Cumulative Fiscal Year-To-Date Distribution Rate is the dollar value of distributions for the current fiscal period November 1, 2024 through June 30, 2025 as a percentage of the Fund's NAV as of June 30, 2025. The level of distribution amount shown is not guaranteed and special dividends may or may not be paid in the future. Further, no conclusions should be drawn about the Fund's investment performance from the amount or rate of distribution shown. Managed Distribution Plan. The above distribution was declared in accordance with the Fund's currently effective managed distribution plan (the 'Plan'), whereby the Fund will make monthly distributions to shareholders at a fixed amount of $0.085 per share. Thus, the distribution amount shown excludes special dividends (which are not paid pursuant to the plan). The Fund will generally distribute amounts necessary to satisfy the Fund's Plan and the requirements prescribed by excise tax rules and Subchapter M of the Internal Revenue Code. The Plan is intended to provide shareholders with a constant, but not guaranteed, fixed minimum rate of distribution each month and is intended to narrow the discount between the market price and the net asset value of the Fund's common shares, but there is no assurance that the Plan will be successful in doing so. Under the Plan, to the extent that sufficient investment income is not available on a monthly basis, the Fund will distribute long-term capital gains and/or return of capital in order to maintain its managed distribution rate. As a result, long-term capital gains and/or return of capital may be a material source of any distribution. No conclusions should be drawn about the Fund's investment performance from the amount of the Fund's distributions or from the terms of the Fund's Plan. The Board of Trustees (the 'Board') may amend the terms of the Plan or terminate the Plan at any time without prior notice to Fund shareholders. No level of distribution can be guaranteed. The amendment or termination of the Plan could have an adverse effect on the market price of the Fund's common shares. The Plan is subject to the periodic review by the Board, including a yearly review of the annual minimum fixed rate to determine if an adjustment should be made. Past Performance is No Assurance of Future Results. Investment return and principal value of an investment in the Fund will fluctuate. Shares, when sold, may be worth more or less than their original cost. Investors should consider the investment objective, risks and expenses carefully. You can obtain the Fund's most recent periodic reports and filings by visiting Other Information and Certain Risk Factors: The Fund's investment objective is to provide investors with a high level of current income, with a secondary goal of capital appreciation. There can be no assurance that the Fund will meet its investment objective. The Fund seeks to achieve this objective by investing globally in debt and equity securities of public and private companies, which includes, among other things, investments in closed‐end funds, special purpose acquisition companies ('SPACs'), reinsurance, and public and private debt instruments. The Fund also may utilize derivatives including but not limited to total return swaps, credit default swaps, options and futures, in seeking to enhance returns and/or to reduce portfolio risk. The value of the Fund's investments in equity securities of public and private, listed and unlisted companies and equity derivatives generally varies with the performance of the issuer and movements in the equity markets more generally. As a result, the Fund may suffer losses if it invests in equity instruments of issuers whose performance diverges from the Fund's investment manager's expectations or if equity markets generally move in a single direction and the Fund has not hedged against such a general move. The Fund invests in closed-end funds and SPACs, which are subject to additional risks and considerations. The performance of reinsurance-related securities and the reinsurance industry itself are tied to the occurrence of various triggering events, including but not limited to weather, natural disasters (hurricanes, earthquakes, etc.), non-natural large catastrophes and other specified events causing physical and/or economic loss. To the extent the Fund invests in reinsurance-related securities for which a triggering event occurs, losses associated with such event could result in losses to the Fund's investment, and a series of major triggering events affecting a large portion of the reinsurance- related securities held by the Fund could result in substantial losses to the Fund's investment. The Fund may invest in high yield securities, which are speculative in nature and are subject to additional risk factors such as increased possibility of default, illiquidity of the security, and changes in value based on changes in interest rates. Changes in short-term market interest rates may directly affect the yield on the Fund's common shares. If such rates fall, the Fund's yield may also fall. If interest rate spreads on bonds and loans owned by the Fund decline in general, the yield on the bonds and loans will likely fall and the value of such bonds and loans may decrease. When short-term market interest rates rise, because of the lag between changes in such short-term rates and the resetting of the floating rates on bonds and loans in the Fund's portfolio, the impact of rising rates will be delayed to the extent of such lag. Because of the limited secondary market for certain bonds and loans, the Fund's ability to sell such securities in a timely fashion and/or at a favorable price may be limited. An increase in the demand for bonds and loans may adversely affect the rate of interest payable on new bonds and loans acquired by the Fund, and it may also increase the price of bonds and loans purchased by the Fund in the secondary market. A decrease in the demand for bonds and loans may adversely affect the price of bonds and loans in the Fund's portfolio, which would cause the Fund's net asset value to decrease. The Fund's use of leverage, if any, through borrowings or issuance of preferred shares can adversely affect the yield on the Fund's common shares. Investment in foreign borrowers involves special risks, including but not limited to potentially less rigorous accounting requirements, differing legal systems and potential political, social and economic adversity. The Fund may engage in currency exchange transactions to seek to hedge, as closely as practicable, all of the economic impact to the Fund arising from foreign currency fluctuations. Other risks include, but are not limited to, the use of derivatives, the potential lack of diversification in the Fund's portfolio, and the fact that the Fund's portfolio may be concentrated in a small group of industries or industry sectors from time to time. Investors should consult the Fund's filings with the Securities and Exchange Commission as well as the materials on the Fund's website for a more detailed discussion of these or other risk factors that affect the Fund. About Saba Capital Income & Opportunities Fund. Saba Capital Income & Opportunities Fund is a publicly-traded registered closed-end management investment company. The Fund's common shares trade on the New York Stock Exchange under the ticker symbol 'BRW'. The Fund is managed by Saba Capital Management, L.P. Forward-Looking Statements. This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including but not limited to statements containing the words 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates' and similar expressions) should also be considered to be forward-looking statements. These statements are not guarantees of future performance, conditions or results and involve a number of risks and uncertainties. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors, including but not limited to the 'Certain Risk Factors' noted above, are identified from time to time in the Fund's filings with the Securities and Exchange Commission as well as the materials on the Fund's website. The Fund undertakes no obligation to update such statements to reflect subsequent events, except as may be required by law.
